Depatuxizumab MMAE
Depatuxizumab MMAE is an advanced Antibody-Drug Conjugate (ADC) for targeted cancer therapy. It combines a monoclonal antibody targeting Epidermal Growth Factor Receptor (EGFR) with monomethyl auristatin E (MMAE), a powerful cytotoxic agent. It focuses on cancer cells that overexpress EGFR, delivering strong results with fewer side effects.
Features
- Target-Specific Action: Targets EGFR, often overexpressed in many cancers.
- Smart Drug Delivery: Delivers MMAE directly into cancer cells using an efficient linker.
- High Potency: Breaks down microtubules, stopping cancer cells from dividing and growing.
- Reduced Toxicity: Shows minimal unwanted effects in preclinical tests.
- Versatile Use: Works well in preclinical studies of EGFR-positive cancers.
Applications
- Oncology Research: Tests treatments for EGFR-positive cancers like glioblastoma, NSCLC, and head and neck cancers.
- Therapeutic Development: Advances ADC technology in cancer therapy.
- Resistance Studies: Examines why tumors resist EGFR-targeted treatments.
- Precision Medicine: Helps develop therapies for patients with specific cancer traits.
- Preclinical Testing: Evaluates targeted cancer treatments in labs and animal studies.
Important Note
Depatuxizumab MMAE is for research and clinical trials only. It is not approved for general medical use.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.